Search

BioNTech SE ADR

Nyitva

SzektorEgészségügy

91.53 -1.21

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

91.16

Maximum

94.33

Fő mutatók

By Trading Economics

Bevétel

-239M

-541M

Értékesítés

-779M

120M

Egy részvényre jutó nyereség

-1.95

Profit margin

-450.381

Munkavállalók

7,807

EBITDA

-383M

-450M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+35.35% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-1.4B

24B

Előző nyitás

92.74

Előző zárás

91.53

Hangulat hírek alapján

By Acuity

36%

64%

139 / 342 Rangsor szerint Healthcare

BioNTech SE ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 9. 23:56 UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

2026. júl. 9. 23:51 UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

2026. júl. 9. 23:51 UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

2026. júl. 9. 23:46 UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

2026. júl. 9. 23:36 UTC

News

Starbucks is developing AI tools to save $2 billion, including $400 million in software costs. Shares are higher in after-market trading.

2026. júl. 9. 23:16 UTC

News

Micron Technology expands U.S. investment to $250 billion by 2035, boosting capital expenditures by $50 billion. Shares rise in after-market trading.

2026. júl. 9. 23:06 UTC

Social Media
News

Tesla shares declined in after-market trading following a Hold rating from Citizens' Andrew Boone, who cited caution on the company's AI timeline.

2026. júl. 9. 20:07 UTC

News

BMO Capital initiated coverage on Align Technology with an Outperform rating and a price target of $209, contributing to positive sentiment despite leadership changes.

2026. júl. 9. 20:07 UTC

Correlated Moves
News

The iShares Core U.S. Aggregate Bond ETF is advancing today, supported by a decline in Treasury yields and positive labor market data.

2026. júl. 9. 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

SPDR S&P 500 ETF Trust advances amid mixed market sentiment and geopolitical tensions. Initial jobless claims fell to 215,000, supporting positive momentum.

2026. júl. 9. 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

The iShares Russell 2000 ETF is gaining amid geopolitical tensions and positive economic indicators, despite earlier fluctuations in the session.

2026. júl. 9. 20:07 UTC

Social Media
News
Correlated Moves
Macro Event

The iShares iBoxx $ Investment Grade Corporate Bond ETF and iShares TIPS Bond ETF are trading higher, supported by falling Treasury yields and improved jobless claims.

2026. júl. 9. 20:07 UTC

News
Social Media

Alphabet Inc. shares are lower amid concerns about its AI competitiveness, as a report suggests Meta may surpass Google in frontier AI capabilities.

2026. júl. 9. 20:07 UTC

Social Media
Correlated Moves
News

Western Digital shares rise as Micron plans $250 billion investment in U.S. memory production, boosting demand and pricing in the memory chip sector.

2026. júl. 9. 20:07 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials shares advanced on analyst target increases amid strong demand outlook. The Nasdaq 100's rise also supported the stock's performance.

2026. júl. 9. 20:07 UTC

Social Media
News
Correlated Moves

Broadcom Inc gains as it joins Morningstar's "Cheap Stocks to Buy" list and announces a multiyear, $30 billion partnership with Apple for chip production.

2026. júl. 9. 20:07 UTC

Correlated Moves
Social Media
News

Citibank's CIO survey shows Microsoft leads AI funding, with 69% from new budgets. Shares are trading higher amid positive sentiment and ongoing challenges.

2026. júl. 9. 20:07 UTC

News
Correlated Moves

Ethereum sees $70 million in ETF inflows, the largest in 28 days. Despite negative social media sentiment, the asset is trading higher since Wednesday's close.

2026. júl. 9. 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's policy review may also support investor confidence in the cryptocurrency.

2026. júl. 9. 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's review of monetary policy may also boost investor confidence.

2026. júl. 9. 20:07 UTC

News
Correlated Moves

Ethereum sees significant inflows of $70 million from ETFs, marking the largest daily increase in 28 days, contributing to its higher trading position since Wednesday.

2026. júl. 9. 20:06 UTC

News

J B Hunt Transport Services is higher today after Goldman Sachs and Citigroup raised their price targets, reflecting positive assessments of the company's performance.

2026. júl. 9. 20:06 UTC

News

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims related to the company's financial practices.

2026. júl. 9. 20:06 UTC

Social Media
News

Shares of Alphabet Inc. are lower amid concerns over its AI competitiveness, following a report suggesting Meta may surpass Google in frontier AI capabilities.

2026. júl. 9. 20:06 UTC

Event
News
Social Media
Correlated Moves

Intuit Inc. shares rise as the company goes ex-dividend for $1.20. Investor interest grows amid overall market strength and positive sentiment in technology stocks.

2026. júl. 9. 20:06 UTC

News
Correlated Moves

Geopolitical tensions following U.S. airstrikes on Iran have increased demand for safe-haven currencies, with CHF/HKD trading slightly higher during Thursday's session.

2026. júl. 9. 20:03 UTC

News
Social Media
Event
Macro Event

PepsiCo Inc's stock is lower following mixed second-quarter earnings, with revenue at $24.18 billion but adjusted EPS of $2.20 missing estimates.

2026. júl. 9. 20:02 UTC

News

Cisco Systems is trading higher as investors respond to its focus on smart building technology, including a partnership showing significant energy efficiency gains.

2026. júl. 9. 20:02 UTC

Social Media
ETF Constituents
News

Invesco QQQ Trust trades higher, recovering above $713.75, as SpaceX's Nasdaq-100 inclusion boosts interest. Strong performances from Meta, Broadcom, and AMD support the ETF.

2026. júl. 9. 20:02 UTC

Macro Event
News
Social Media
Correlated Moves

KLA shares advance as TD Cowen raises price target to $260. Positive sentiment in the semiconductor sector supports the upward movement amid increased AI demand.

Társak összehasonlítása

Árváltozás

BioNTech SE ADR Előrejelzés

Célár

By TipRanks

35.35% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 125.85 USD  35.35%

Magas 158 USD

Alacsony 94 USD

13 Wall Street elemző 12 hónapos célárain alapulva a(z)BioNTech SE ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

13 ratings

10

Vétel

3

Tartás

0

Eladás

Hangulat

By Acuity

139 / 342 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
help-icon Live chat